Population pharmacokinetics of transdermal fentanyl in patients with cancer-related pain

Journal of Pain and Palliative Care Pharmacotherapy

Volumn 26, Issue 2, 2012, Pages 98-104

  Kokubun, Hideya ^a   Ebinuma, Keiichi ^b   Matoba, Motohiro ^c   Takayanagi, Risa ^d   Yamada, Yasuhiko ^d   Yago, Kazuo ^a,e  

^a KITASATO UNIVERSITY HOSPITAL   (Japan)

^b JICHI MEDICAL UNIVERSITY   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL   (Japan)

^d TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

^e KITASATO UNIVERSITY   (Japan)

Author keywords

Cancer patient; Child Pugh Score; CYP3A4 inducer; Fentanyl patch; Palliative care; Population pharmacokinetics

Indexed keywords

CARBAMAZEPINE; CYTOCHROME P450 3A4; DUROTEP PATCH; FENTANYL; PHENOBARBITAL; UNCLASSIFIED DRUG;

ADULT; AGED; ANALGESIA; ARTICLE; BLOOD SAMPLING; CANCER PAIN; DRUG BLOOD LEVEL; DRUG MEGADOSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; NONLINEAR SYSTEM; PREDICTION; TRANSDERMAL PATCH;

ADMINISTRATION, CUTANEOUS; ADULT; AGED; ANALGESICS, OPIOID; CYTOCHROME P-450 CYP3A; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INDUCTION; FEMALE; FENTANYL; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; NEOPLASMS; NONLINEAR DYNAMICS; PAIN; TIME FACTORS; TRANSDERMAL PATCH;

EID: 84863575465     PISSN: 15360288     EISSN: 15360539     Source Type: Journal    
DOI: 10.3109/15360288.2012.679725     Document Type: Article

References (21)

1. Chen JC, Smith ER, Cahill M, Cohen R, Fishman JB. The opioid receptor binding of dezocine, morphine, fentanyl, butorphanol and nalbuphine. Life Sci. 1993;52:389-396.
2. Radbruch L, Sabatowski R, Loick G, et al. Constipation and the use of laxatives: A comparison between transdermal fentanyl and oral morphine. Palliat Med. 2000;14:111-119.
3. Schneider E, Brune K. Opioid activity and distribution of fentanyl metabolites. Naunyn Schmiedebergs Arch Pharmacol. 1986;334:267-274.
4. King S, Forbes K, Hanks GW, Ferro CJ, Chambers EJ. A systematic review of the use of opioid medication for those with moderate to severe cancer pain and renal impairment: A European Palliative Care Research Collaborative opioid guidelines project. Palliative Med. 2011;25:525-552.
5. Kokubun H, Matoba M, Hoka S, Yamada Y, Yago K. Relationship between serum fentanyl concentration and transdermal fentanyl dosage, and intra-Individual variability in fentanyl concentration after application of fentanyl patches in patients with cancer pain. Jpn J Pharm Health Care Sci. 2007;33:200-205.
6. Levron JC. Pharmacokinetic study of fentanyl administered transdermally (TTS) to patients with liver disorder. Tokyo: JANSSEN Inc., in house document for NDA 1992.
7. AshburnMA, OgdenLL,Zhang J, LoveG, Basta SV. The pharmacokinetics of transdermal fentanyl delivered with and without controlled heat. J Pain. 2003;4:291-297.
8. Tempelhoff R, Modica PA, Spitznagel EL Jr. Anticonvulsant therapy increases fentanyl requirements during anaesthesia for craniotomy. Can J Anaesth. 1990;37:327-332.
9. Olkkola KT, Palkama VJ, Neuvonen PJ. Ritonavir's role in reducing fentanyl clearance and prolonging its half-Life. Anesthesiology. 1999;91:681-685.
10. Hallberg P, Marten L, Wadelius M. Possible fluconazolefentanyl interaction-A case report. Eur J Clin Pharmacol. 2006;62:491-492.
11. Kharasch ED, Whittington D, Hoffer C. Influence of hepatic and intestinal cytochrome P4503A activity on the acute disposition and effects of oral transmucosal fentanyl citrate. Anesthesiology. 2004;101:729-737.
12. Kokubun H, Matoba M, Okazaki M, Hoka S, Yago K. Evaluation of the 2.5 mg fentanyl patch, applied using the half-Side application procedure in patients with cancer pain. Yakugaku Zasshi. 2008;128:447-450.
13. Numata C, Teraoka R, Matsuda Y, et al. Investigation of residual amount of fentanyl in used transdermal fentanyl patches: Effects of person applying patch and application site. Jpn J Pharm Health Care Sci. 2005;31:599-605.
14. Nakayama H, Hasegawa T, Morikawa A, Sugibayashi K. Prediction of serum profile of fentanyl after repeated application of Durotep R® patch on skin. Jpn J Ther Drug Monit. 2004;21:248-225.
15. Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982-992.
16. McClain DA, Hug CC Jr. Intravenous fentanyl kinetics. Clin Pharmacol Ther. 1980;28:106-114.
17. Murphy MR, Hug CC Jr, McClain DA. Dose-Independent pharmacokinetics of fentanyl. Anesthesiology. 1983;59:537-540.
18. Ariano RE, Duke PC, Sister DS. Population pharmacokinetics of fentanyl in healthy volunteers. J Clin Pharmacol. 2001;41:757-763.
19. Feierman DE, Lasker JM. Metabolism of fentanyl, a synthetic opioid analgesic, by human liver microsomes. Role of CYP3A4. Drug Metab Dispos. 1996;24:932-939.
20. Tateishi T, Krivoruk Y, Ueng YF, Wood AJJ, Guengerich FP, Wood M. Identification of human liver cytochrome P-450 3A4 as the enzyme responsible for fentanyl and sufentanil Ndealkylation. Anesth Analg. 1996;82:167-172.
21. Ohtsuka H, Kobayashi H, Shigeoka T, Torii S, Shimomura H, Nemoto H. Absorption, distribution, metabolism and excretion of 3H-Fentanyl after subcutaneous administration in rats. Jpn Pharmacol Ther. 2001;29:865-876.